Investing since 2009, we focus exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Aligning with AbbVie’s strategic focus, our investments address critical needs in oncology, immunology, neuroscience, eye care, and aesthetics. We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization.
Our current portfolio is comprised of over 20 companies based in the US and Europe. Targeting six to eight new investments annually, predominantly at the Seed or Series A stage, we have the capability and flexibility to create new companies, and lead or co-lead a syndicate. Our team of dedicated investing professionals is based in three locations: Cambridge (MA), San Francisco (CA), and Oxford (UK).